JP2024538769A5 - - Google Patents
Info
- Publication number
- JP2024538769A5 JP2024538769A5 JP2024522030A JP2024522030A JP2024538769A5 JP 2024538769 A5 JP2024538769 A5 JP 2024538769A5 JP 2024522030 A JP2024522030 A JP 2024522030A JP 2024522030 A JP2024522030 A JP 2024522030A JP 2024538769 A5 JP2024538769 A5 JP 2024538769A5
- Authority
- JP
- Japan
- Prior art keywords
- homologous
- region
- chr
- seq
- identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2114587.5A GB202114587D0 (en) | 2021-10-12 | 2021-10-12 | Polynucleotide |
| GB2114587.5 | 2021-10-12 | ||
| GB2205593.3 | 2022-04-14 | ||
| GBGB2205593.3A GB202205593D0 (en) | 2022-04-14 | 2022-04-14 | Polynucleotide |
| PCT/EP2022/078298 WO2023062030A1 (en) | 2021-10-12 | 2022-10-11 | Polynucleotides useful for correcting mutations in the rag1 gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024538769A JP2024538769A (ja) | 2024-10-23 |
| JP2024538769A5 true JP2024538769A5 (enExample) | 2026-02-17 |
Family
ID=84360322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522030A Pending JP2024538769A (ja) | 2021-10-12 | 2022-10-11 | Ｒａｇ１遺伝子における突然変異を修正するのに有用なポリヌクレオチド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240425851A1 (enExample) |
| EP (1) | EP4416171A1 (enExample) |
| JP (1) | JP2024538769A (enExample) |
| CA (1) | CA3234828A1 (enExample) |
| IL (1) | IL312062A (enExample) |
| WO (1) | WO2023062030A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2325003B (en) | 1996-10-17 | 2000-05-10 | Oxford Biomedica Ltd | Rectroviral vectors |
| WO2017134529A1 (en) * | 2016-02-02 | 2017-08-10 | Crispr Therapeutics Ag | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
| CN112601812A (zh) | 2018-06-25 | 2021-04-02 | 圣拉斐尔医院有限责任公司 | 基因疗法 |
| IL302031A (en) * | 2020-10-12 | 2023-06-01 | Ospedale San Raffaele Srl | Replacement of rag1 for use in therapy |
-
2022
- 2022-10-11 EP EP22808606.2A patent/EP4416171A1/en active Pending
- 2022-10-11 US US18/700,795 patent/US20240425851A1/en active Pending
- 2022-10-11 CA CA3234828A patent/CA3234828A1/en active Pending
- 2022-10-11 IL IL312062A patent/IL312062A/en unknown
- 2022-10-11 WO PCT/EP2022/078298 patent/WO2023062030A1/en not_active Ceased
- 2022-10-11 JP JP2024522030A patent/JP2024538769A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7651190B2 (ja) | 遺伝子操作ｒｎａを用いた内因性ａｄａｒによる標的化ｒｎａ編集 | |
| CN108350454B (zh) | 等位基因选择性基因编辑及其用途 | |
| Decker et al. | The expression of the Ig H chain repertoire in developing bone marrow B lineage cells | |
| WO1996038176A1 (fr) | Inhibiteur de la croissance de cellules leucemiques contenant des derives oligonucleotidiques antisens agissant contre le gene de la tumeur de wilms (wt1) | |
| AU2021282533A1 (en) | Optimized crispr/cas9 systems and methods for gene editing in stem cells | |
| JP2023544633A5 (enExample) | ||
| JP2024501246A5 (enExample) | ||
| EP0575518A1 (en) | Methods and compositions for the selective inhibition of gene expression | |
| US5580703A (en) | Human adeno-associated virus integration site DNA and uses thereof | |
| US7696150B2 (en) | Modulation of the activity of an interleukin 17 receptor-related protein, EVI27, and uses thereof | |
| JP2024518817A5 (enExample) | ||
| JP2023504826A5 (enExample) | ||
| Van Coillie et al. | The human MCP-2 gene (SCYA8): cloning, sequence analysis, tissue expression, and assignment to the CC chemokine gene contig on chromosome 17q11. 2 | |
| Kim et al. | The structure and evolution of the human salivary proline-rich protein gene family | |
| Shirai et al. | Cloning and expression in Escherichia coli of the gene for mouse tumor necrosis factor | |
| JP3373856B2 (ja) | Ｇｐ１３０に全く結合することができないヒトインターロイキン−６の拮抗薬、および医薬化合物の製造におけるそれらの使用 | |
| KR102428773B1 (ko) | 분리형 crRNA 및 이를 이용한 CRISPR-Cas 시스템 | |
| JP2024528967A5 (enExample) | ||
| JP2024529108A5 (enExample) | ||
| JP2024520691A5 (enExample) | ||
| JP2024521750A5 (enExample) | ||
| Snouwaert et al. | Large numbers of random point and cluster mutations within the adenovirus VA I gene allow characterization of sequences required for efficient transcription | |
| Chan et al. | The structure of a gene containing introns and encoding rat ribosomal protein P2 | |
| JP2022539569A5 (enExample) | ||
| US5959094A (en) | p75 TNF receptor promoters |